HK1152947A1 - Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6 - Google Patents

Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6

Info

Publication number
HK1152947A1
HK1152947A1 HK11106921.8A HK11106921A HK1152947A1 HK 1152947 A1 HK1152947 A1 HK 1152947A1 HK 11106921 A HK11106921 A HK 11106921A HK 1152947 A1 HK1152947 A1 HK 1152947A1
Authority
HK
Hong Kong
Prior art keywords
trpv6
inhibiting
cancer treatment
calcium channel
channel activity
Prior art date
Application number
HK11106921.8A
Other languages
English (en)
Chinese (zh)
Inventor
John M Stewart
Original Assignee
Soricimed Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soricimed Biopharma Inc filed Critical Soricimed Biopharma Inc
Publication of HK1152947A1 publication Critical patent/HK1152947A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK11106921.8A 2008-03-19 2011-07-05 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6 HK1152947A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3790308P 2008-03-19 2008-03-19
PCT/CA2009/000343 WO2009114943A1 (en) 2008-03-19 2009-03-18 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity

Publications (1)

Publication Number Publication Date
HK1152947A1 true HK1152947A1 (en) 2012-03-16

Family

ID=41090452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106921.8A HK1152947A1 (en) 2008-03-19 2011-07-05 Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6

Country Status (7)

Country Link
US (4) US8211857B2 (de)
EP (1) EP2268665B1 (de)
JP (1) JP5749154B2 (de)
CA (1) CA2718949C (de)
ES (1) ES2530091T3 (de)
HK (1) HK1152947A1 (de)
WO (1) WO2009114943A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114943A1 (en) 2008-03-19 2009-09-24 Bioprospecting Nb, Inc. Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity
BRPI1012675A2 (pt) * 2009-06-26 2016-04-05 Soricimed Biopharma Inc compostos e métodos para a detecção de cânceres expressando trpv-6 e liberação de fármacos
EP2895504B1 (de) 2012-09-14 2019-05-08 John M. Stewart Trpv3-agonisten zur behandlung von hauterkrankungen
EP3397267A4 (de) 2015-11-02 2019-08-21 University of New Brunswick Peptide zur behandlung von resorptiver knochenerkrankung
EP3716991A4 (de) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. Trpv6 -inhibitoren und kombinationstherapien zur behandlung von krebs
CN113072634B (zh) * 2021-03-17 2022-07-12 西安交通大学 一种胞膜瞬时受体电位c6通道免疫原性短肽及其疫苗和抗心室纤维化的制药应用
KR20240099277A (ko) 2021-10-14 2024-06-28 위니베르시떼 드 릴르 인간 trpv6 채널의 세포외 에피토프에 대한 항체와 이의 진단 및 치료 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JPH10236963A (ja) 1997-02-26 1998-09-08 Sagami Chem Res Center カルシウムチャンネル拮抗剤
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent
EP1165508B1 (de) * 1999-04-07 2004-06-23 The University of Virginia Patent Foundation Calciumkanalblocker als antikrebsmittel
US6946475B1 (en) * 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
US6534642B1 (en) * 1999-07-09 2003-03-18 Matthias A. Hediger Compositions corresponding to a calcium transporter and methods of making and using same
ATE396266T1 (de) * 2000-07-28 2008-06-15 Ulrich Wissenbach Trp8 krebsmarker
US7119168B2 (en) * 2002-11-18 2006-10-10 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
DE60318749T2 (de) * 2002-11-18 2009-01-22 Bioprospecting Nb Inc. Paralytisches peptid von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
WO2009114943A1 (en) 2008-03-19 2009-09-24 Bioprospecting Nb, Inc. Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity

Also Published As

Publication number Publication date
US10058587B2 (en) 2018-08-28
US20120316119A1 (en) 2012-12-13
ES2530091T3 (es) 2015-02-26
EP2268665B1 (de) 2014-11-12
JP5749154B2 (ja) 2015-07-15
WO2009114943A1 (en) 2009-09-24
CA2718949C (en) 2021-05-04
EP2268665A1 (de) 2011-01-05
US20110071089A1 (en) 2011-03-24
EP2268665A4 (de) 2011-05-18
US8211857B2 (en) 2012-07-03
US9303077B2 (en) 2016-04-05
US20160206694A1 (en) 2016-07-21
US20140187493A1 (en) 2014-07-03
JP2011517442A (ja) 2011-06-09
US8618058B2 (en) 2013-12-31
CA2718949A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
IL229878A (en) Cancer Treatment Compounds
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
HK1173153A1 (en) Compounds useful for treating cancer
IL199907A0 (en) Composition for treatment of pancreatic cancer
EP1996612A4 (de) Zusammensetzungen zur behandlung von krebs
EP2152722A4 (de) Mir34-therapeutika enthaltende zusammensetzungen zur behandlung von krebs
SI2310034T1 (sl) Peptidi za zdravljenje beta-amiloidoz
HK1152947A1 (en) Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity trpv6
IL209156A0 (en) Opioid composition for treating skin lesions
EP1987838A4 (de) Neue verbindung zur tumortherapie
IL213398A0 (en) Compounds for treating cancer
EP2327402A4 (de) Zusammensetzung mit 4-o-methylhonokiol zur behandlung oder prävention amyloid-bedingter erkrankungen
IL211904A0 (en) Composition for treating disese
EP2374463A4 (de) Zusammensetzung zur verbesserung der strahlentherapie gegen krebs
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2255825A4 (de) Zusammensetzung zur prävention oder behandlung von gehirnerkrankungen
EP2174956A4 (de) Zusammensetzungen für eine antifibrinolysetherapie
EP1986656A4 (de) Withacnistin-verbindungen zur behandlung von krebs
IL209999A0 (en) Nifurtimox for treating diseases caused by trichomonadida
EP2473506A4 (de) Verbindungen und verfahren zur behandlung von krebs
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0707556D0 (en) Treatment for cancer
EP2214485A4 (de) Verfahren für die behandlung von krebs
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
GB0817056D0 (en) Polypeptide for treatment of cancer